凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2013年第一季度报告全文

公告日期 2013-04-20
股票简称:海普瑞 股票代码:002399
               深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文深圳市海普瑞药业股份有限公司
    2013 年第一季度报告
        2013 年 04 月
                                                   深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                                   第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人员)孔芸声明:保证季度报告中财务报表的真实、准确、完整。
    所有董事均已出席了审议本次季报的董事会会议。
                                                            深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                            第二节 主要财务数据及股东变化一、主要财务数据
    本报告期对以前期间财务数据是否进行了追溯调整或重述
    □ 是 √ 否
                                                                                              本报告期比上年同期增减
                                         2013 年 1-3 月              2012 年 1-3 月
                                                                                                      (%)
    营业收入(元)                                450,657,197.79               487,552,877.32                       -7.57%
    归属于上市公司股东的净利润(元)              139,102,767.21               173,549,408.91                      -19.85%归属于上市公司股东的扣除非经常性损
                                              139,757,795.73               173,438,808.31                      -19.42%益的净利润(元)
    经营活动产生的现金流量净额(元)               48,828,624.18               489,390,758.88                      -90.02%
    基本每股收益(元/股)                                       0.17                       0.22                    -22.73%
    稀释每股收益(元/股)                                       0.17                       0.22                    -22.73%
    加权平均净资产收益率(%)                                 1.72%                        2.2%                     -0.48%
                                                                                              本报告期末比上年度期末
                                       2013 年 3 月 31 日          2012 年 12 月 31 日
                                                                                                     增减(%)
    总资产(元)                                 8,378,089,260.64            8,259,893,243.21                       1.43%
    归属于上市公司股东的净资产(元)             8,166,230,984.16            7,961,506,212.56                       2.57%
    注:报告期内公司归属于上市公司股东的净利润较去年同期下降,主要原因是肝素钠原料药销售价格略有下降且肝素粗品原料采购价格上涨带来营业成本的上升,导致毛利率较去年同期下降所致。
    非经常性损益项目和金额
    √ 适用 □ 不适用
                                                                                                              单位:元
                        项目                                年初至报告期期末金额                    说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                   -336,627.28计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          167,027.73一标准定额或定量享受的政府补助除外)除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                                         -529,830.00处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                                        5,087.78
                                                           深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    其他符合非经常性损益定义的损益项目                                           1,580.00
    所得税影响额                                                               -65,194.08
    少数股东权益影响额(税后)                                                 27,460.83
    合计                                                                      -655,028.52              --二、报告期末股东总数及前十名股东持股情况表
                                                                                                         单位:股
    报告期末股东总数                                                                                             42,063
                                              前 10 名股东持股情况
                                                                   持有有限售条件           质押或冻结情况
    股东名称        股东性质      持股比例(%)   持股数量
                                                                     的股份数量         股份状态        数量深圳市乐仁科技
                  境内非国有法人          36.94%     295,562,100       295,560,000有限公司深圳市金田土科
                  境内非国有法人          31.87%     255,025,800       255,024,000技有限公司GS DIRECT
    PHARMA            境外法人                 4.84%      38,706,161                  0LIMITED深圳市水滴石穿
                  境内非国有法人           3.63%      29,016,000        29,016,000科技有限公司湖南应时信息科
                  境内非国有法人           3.15%      25,200,000        25,200,000技有限公司深圳市飞来石科
                  境内非国有法人           3.15%      25,200,000        25,200,000技有限公司中国中投证券有限责任公司客户
                  境内非国有法人           0.35%       2,813,881                  0信用交易担保证券账户中国银行-嘉实沪深 300 交易型
                  境内非国有法人           0.13%       1,068,357                  0开放式指数证券投资基金中国建设银行-中小企业板交易
                  境内非国有法人           0.09%        695,570                   0型开放式指数基金
    黄镇              境内自然人               0.08%        654,772                   0
                                                            深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                                          前 10 名无限售条件股东持股情况
                                                                                             股份种类
           股东名称                          持有无限售条件股份数量
                                                                                     股份种类           数量
    GS DIRECT PHARMA LIMITED                                              38,706,161 人民币普通股           38,706,161中国中投证券有限责任公司客户
                                                                       2,813,881 人民币普通股            2,813,881信用交易担保证券账户中国银行-嘉实沪深 300 交易型开
                                                                       1,068,357 人民币普通股            1,068,357放式指数证券投资基金中国建设银行-中小企业板交易
                                                                           695,570 人民币普通股           695,570型开放式指数基金
    黄镇                                                                       654,772 人民币普通股           654,772
    广州融达电源材料有限公司                                                   647,550 人民币普通股           647,550
    莫顺娴                                                                     641,089 人民币普通股           641,089中国工商银行-华夏沪深 300 交易
                                                                           596,100 人民币普通股           596,100型开放式指数证券投资基金国信证券股份有限公司客户信用
                                                                           544,922 人民币普通股           544,922交易担保证券账户中信建投证券股份有限公司客户
                                                                           535,318 人民币普通股           535,318信用交易担保证券账户
                                  深圳市乐仁科技有限公司和深圳市金田土科技有限公司的股东为李锂和李坦,深圳市飞
                                  来石科技有限公司的股东为李锂,深圳市水滴石穿科技有限公司的股东为单宇和李坦,上述股东关联关系或一致行动的
                                  李锂和李坦为夫妻关系,单宇和李坦为兄妹关系。除上述情况外,公司未知其他前十名说明
                                  股东之间是否存在关联关系,也未知是否属于一致行动人;公司未知其他前十名无限售
                                  条件股东之间是否存在关联关系,也未知是否属于一致行动人。
                                                   深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                                    第三节 重要事项一、 报告期主要会计报表项目、财务指标发生重大变动的情况及原因
       (一)资产负债表项目
    1、交易性金融资产报告期末余额较上年度末余额减少52.98万元,主要原因系报告期末公司持有远期外汇交易合约到期全部交割所致。
    2、预付款项报告期末余额较上年度末余额增加61.79%,主要原因系报告期预付原材料采购款增加所致。
    3、可供出售的金融资产报告期末余额较上年度末余额增加12,487.75万元,主要原因系报告期公司完成认购Prometic Life Sciences Inc. 增发的48,147,053股股票,确认为可供出售的金融资产以及该资产公允价值变动所致。
    4、递延所得税资产报告期末余额较上年度末余额减少36.47%,主要原因系报告期支付了部分上期末计提的应付职工薪酬,冲回原来计提的递延所得税资产所致。
    5、其他非流动资产报告期末余额较上年度末余额增加92.89%,主要原因系报告期增加预付的土地出让金所致。
    6、短期借款报告期末余额较上年度末余额减少7,316.32万元,主要原因系报告期公司偿还出口押汇借款所致。
    7、 应付账款报告期末余额较上年度末余额减少54.81%,主要原因系报告期支付原材料采购款所致。
    8、预收款项报告期末余额较上年度末余额增加3,793.63%,主要原因系报告期子公司收到客户预付款增加所致。
    9、应付职工薪酬报告期末余额较上年度末余额减少40.93%,主要原因系报告期支付了部分上期末计提的应付职工薪酬所致。
    10、应交税费报告期末余额较上年度末余额增加130.87%,主要原因系计提的企业所得税尚未支付所致。
    11、外币报表折算差额报告期末余额较上年度末余额增加110.10%,主要原因系报告期汇率变动所致。
       (二) 利润表项目
    1、营业税金及附加报告期较上年同期减少69.67%,主要原因系报告期经主管税局核准的当期免抵的增值税税额和当期应缴增值税额较上年同期减少所致。
                                                             深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    2、 销售费用报告期较上年同期减少47.95%,主要原因系报告期参展费减少所致。
    3、管理费用报告期较上年同期增加57.79%,主要原因系报告期母公司研发费用增加以及子公司开始经营相应管理费用增加所致。
    4、公允价值变动收益报告期较上年同期增加99.64万元,主要原因系报告期公司所持有的远期外汇交易合约到期全部交割所致。
    5、营业外支出报告期较上年同期增加4,326.32%,主要原因系报告期子公司固定资产处置增加所致。
    6、少数股东损益报告期较上年同期增加42.62%,主要原因系报告期内少数股东对子公司成都深瑞畜产品有限公司的持股比例减少所致。
       (三) 现金流量表项目
    1、经营活动产生的现金流量净额报告期期较上年同期减少90.02%,主要原因系报告期收到的产品销售收入减少以及原料采购支付增加所致。
    2、投资活动产生的现金流量净额报告期较上年同期增加359.03%,主要原因系报告期募投项目投资额增加以及公司支付土地出让金和对Prometic Life Sciences Inc.进行投资所致。
    3、筹资活动产生的现金流量净额报告期较上年同期减少1,929.16%,主要原因系报告期公司新增出口押汇借款以及偿还所有出口押汇借款所致。
    4、现金及现金等价物净增加额报告期较上年同期减少150.78%,主要原因系经营活动产生的现金流量减少和投资活动产生的现金流量增加、筹资活动产生的现金流量减少共同所致。二、重要事项进展情况及其影响和解决方案的分析说明无。三、公司或持股 5%以上股东在报告期内或持续到报告期内的承诺事项
              承诺事项                  承诺方        承诺内容          承诺时间      承诺期限      履行情况
    股改承诺                             不适用         不适用                         不适用         不适用收购报告书或权益变动报告书中所作承
                                     不适用         不适用                         不适用         不适用诺
    资产重组时所作承诺                   不适用         不适用                         不适用         不适用
                                     公司股东深圳   本公司股东深
                                     市乐仁科技有   圳市乐仁科技
                                                                                                  报告期内,承诺
                                     限公司、深圳市 有限公司、深圳
    首次公开发行或再融资时所作承诺                                                     三十六个月     人严格履行了
                                     金田土科技有   市金田土科技
                                                                                                  上述承诺。
                                     限公司、深圳市 有限公司和深
                                     飞来石科技有   圳市飞来石科
                                                   深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                             限公司         技有限公司承
                                            诺:自公司股票
                                            上市之日起三
                                            十六个月内,不
                                            转让或者委托
                                            他人管理本公
                                            司持有的公司
                                            股份,也不由公
                                            司回购本公司
                                            持有的公司股
                                            份。本承诺所指
                                            股份不包括本
                                            公司在此期间
                                            新增的公司股
                                            份。
                                            一、本公司股东
                                            深圳市乐仁科
                                            技有限公司、深
                                            圳市金田土科
                                            技有限公司和
                                            深圳市飞来石
                                            科技有限公司
                                            承诺:1、在本
                                            公司作为贵司
                                            控股股东期间,
                                            本公司保证不
                             公司股东深圳   自营或以合资、
                             市乐仁科技有   合作等方式经
                             限公司、深圳市 营任何与贵司                                报告期内,承诺
    其他对公司中小股东所作承诺   金田土科技有   现从事的业务                                人严格履行了
                             限公司和深圳   有竞争的业务,                              上述承诺。
                             市飞来石科技   本公司现有的
                             有限公司       或将来成立的
                                            全资子公司、控
                                            股子公司以及
                                            其他受本公司
                                            控制的企业亦
                                            不会经营与贵
                                            司现从事的业
                                            务有竞争的业
                                            务。2、如违反
                                            上述承诺,本公
                                            司同意承担给
                                            贵司造成的全
      深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文部损失。二、公司股东深圳市乐仁科技有限公司和深圳市金田土科技有限公司承诺:如今后公司或子公司深圳市多普生生物技术有限公司因依据深府[1988]232 号文享受的企业所得税优惠被税务机关撤消而产生的额外税项和费用时,将及时、无条件、全额返还公司或深圳市多普生生物技术有限公司补缴的税款以及因此所产生的所有相关费用。三、公司股东深圳市乐仁科技有限公司和深圳市金田土科技有限公司承诺:如今后公司因以实际缴纳的增值税和营业税税额为计税依据缴纳城市维护建设税和教育费附加事宜被税务机关追缴而产生额外税项和费用时,将及时、无条件、全额返还公司补缴的税款以及因此所产生的
                                                          深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                                                    所有相关费用。
                                                    四、公司股东深
                                                    圳市乐仁科技
                                                    有限公司和深
                                                    圳市金田土科
                                                    技有限公司承
                                                    诺:如今后公司
                                                    或子公司深圳
                                                    市多普生生物
                                                    技术有限公司
                                                    因上市前执行
                                                    住房公积金政
                                                    策事宜被要求
                                                    补缴住房公积
                                                    金、缴纳罚款或
                                                    因此遭受任何
                                                    损失时,将及
                                                    时、无条件、全
                                                    额返还公司或
                                                    深圳市多普生
                                                    生物技术有限
                                                    公司由此遭受
                                                    的一切损失。
    承诺是否及时履行                      是
    未完成履行的具体原因及下一步计划      不适用。是否就导致的同业竞争和关联交易问题
                                      是作出承诺
    承诺的解决期限                        不适用。
    解决方式                              不适用。
    承诺的履行情况                        报告期内,承诺人严格履行了上述承诺。四、对 2013 年 1-6 月经营业绩的预计
    2013 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2013 年 1-6 月归属于上市公司股东的净利润变
                                                                       -25%    至                        -5%动幅度(%)2013 年 1-6 月归属于上市公司股东的净利润变
                                                                   24,725.76   至                    31,319.3动区间(万元)
    2012 年 1-6 月归属于上市公司股东的净利润(万                                                        32,967.68
                                                    深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文元)
                                      由于肝素钠原料药销售价格较上年同期有所下降且肝素粗品原料采购价格
    业绩变动的原因说明                    上涨带来营业成本上升的共同影响,导致公司毛利率下降,使得经营业绩
                                      较上年同期下降。五、上市公司发生控股股东及其关联方非经营性占用资金情况
       报告期内,公司不存在控股股东及其关联方非经营性占用资金情况的情况。六、证券投资情况
       报告期内,公司不存在证券投资的情况。
                                                    深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                                  第四节 财务报表一、财务报表1、合并资产负债表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                 单位:元
                 项目                    期末余额                               期初余额流动资产:
    货币资金                                        6,360,496,625.30                       6,588,480,677.31
    结算备付金
    拆出资金
    交易性金融资产                                                                              529,830.00
    应收票据
    应收账款                                         378,952,900.40                         353,798,645.01
    预付款项                                         104,814,462.30                          64,784,443.21
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                         109,206,557.12                          94,103,172.80
    应收股利
    其他应收款                                        74,418,414.42                          97,187,180.76
    买入返售金融资产
    存货                                             561,829,847.43                         548,820,884.93
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                                        7,589,718,806.97                       7,747,704,834.02非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                                 124,877,470.66
    持有至到期投资
    长期应收款
                         深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    长期股权投资
    投资性房地产
    固定资产              213,446,461.67                       187,960,805.31
    在建工程              162,519,751.99                       136,650,626.72
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产               69,372,427.53                        70,051,784.11
    开发支出                  671,178.81                           655,460.11
    商誉
    长期待摊费用            3,364,622.61                         3,429,280.58
    递延所得税资产          2,305,216.61                         3,628,319.51
    其他非流动资产        211,813,323.79                       109,812,132.85
    非流动资产合计            788,370,453.67                       512,188,409.19
    资产总计                 8,378,089,260.64                    8,259,893,243.21流动负债:
    短期借款                                                    73,163,220.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                  356,256.30                          356,256.30
    应付账款               23,793,120.31                        52,646,603.96
    预收款项                4,168,231.22                          107,052.44
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬           14,391,830.33                        24,365,507.01
    应交税费               38,909,282.17                        16,853,566.57
    应付利息
    应付股利
    其他应付款              4,441,101.03                         3,990,029.78
    应付分保账款
    保险合同准备金
                                                  深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                       86,059,821.36                        171,482,236.06非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                 8,402,243.78                          8,587,658.83
    其他非流动负债                                34,298,019.68                         34,461,324.17
    非流动负债合计                                     42,700,263.46                         43,048,983.00
    负债合计                                          128,760,084.82                        214,531,219.06所有者权益(或股东权益):
    实收资本(或股本)                           800,200,000.00                        800,200,000.00
    资本公积                                    5,363,948,007.01                     5,298,038,098.63
    减:库存股
    专项储备
    盈余公积                                     356,181,900.43                        356,181,900.43
    一般风险准备
    未分配利润                                  1,646,450,473.13                     1,507,347,705.92
    外币报表折算差额                                -549,396.41                           -261,492.42
    归属于母公司所有者权益合计                       8,166,230,984.16                     7,961,506,212.56
    少数股东权益                                  83,098,191.66                         83,855,811.59
    所有者权益(或股东权益)合计                     8,249,329,175.82                     8,045,362,024.15负债和所有者权益(或股东权益)总
                                                 8,378,089,260.64                     8,259,893,243.21计
    法定代表人:李锂                   主管会计工作负责人:孔芸                  会计机构负责人:孔芸2、母公司资产负债表编制单位:深圳市海普瑞药业股份有限公司
                                                                                            单位:元
                                        深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
                 项目        期末余额                               期初余额流动资产:
    货币资金                            6,059,857,547.69                       6,333,271,651.85
    交易性金融资产                                                                  529,830.00
    应收票据
    应收账款                             375,414,465.70                         350,220,415.85
    预付款项                             107,404,835.20                          56,859,315.19
    应收利息                             109,206,557.12                          93,218,552.35
    应收股利
    其他应收款                           109,521,918.73                         129,942,523.08
    存货                                 550,067,542.24                         529,448,922.51
    一年内到期的非流动资产
    其他流动资产                         110,000,000.00                         110,000,000.00
    流动资产合计                            7,421,472,866.68                       7,603,491,210.83非流动资产:
    可供出售金融资产                     124,877,470.66
    持有至到期投资
    长期应收款
    长期股权投资                         469,322,508.99                         389,322,508.99
    投资性房地产
    固定资产                              47,601,404.18                          47,421,743.14
    在建工程                              78,939,696.60                          64,029,611.83
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                               3,014,314.76                           2,972,012.91
    开发支出                                 671,178.81                             655,460.11
    商誉
    长期待摊费用
    递延所得税资产                         2,305,216.61                           3,628,319.51
    其他非流动资产                       203,001,638.44                          91,848,167.15
    非流动资产合计                           929,733,429.05                         599,877,823.64
    资产总计                                8,351,206,295.73                       8,203,369,034.47
                               深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文流动负债:
    短期借款                                                          73,163,220.00
    交易性金融负债
    应付票据
    应付账款                      8,227,682.67                        25,404,973.49
    预收款项                         34,319.22                            32,612.44
    应付职工薪酬                 14,330,701.45                        23,143,474.22
    应交税费                     43,889,104.16                        21,224,080.62
    应付利息
    应付股利
    其他应付款                    6,354,091.97                         3,864,028.94
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                     72,835,899.47                       146,832,389.71非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                                                        79,474.50
    其他非流动负债               23,347,863.34                        23,435,881.84
    非流动负债合计                   23,347,863.34                        23,515,356.34
    负债合计                         96,183,762.81                       170,347,746.05所有者权益(或股东权益):
    实收资本(或股本)          800,200,000.00                       800,200,000.00
    资本公积                   5,370,105,872.83                    5,303,818,483.08
    减:库存股
    专项储备
    盈余公积                    356,181,900.43                       356,181,900.43
    一般风险准备
    未分配利润                 1,728,534,759.66                    1,572,820,904.91
    外币报表折算差额
    所有者权益(或股东权益)合计   8,255,022,532.92                    8,033,021,288.42
                                                           深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文负债和所有者权益(或股东权益)总
                                                           8,351,206,295.73                       8,203,369,034.47计
    法定代表人:李锂                         主管会计工作负责人:孔芸                 会计机构负责人:孔芸3、合并利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                        单位:元
                   项目                         本期金额                               上期金额
    一、营业总收入                                              450,657,197.79                         487,552,877.32
       其中:营业收入                                       450,657,197.79                         487,552,877.32
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                              283,690,532.88                         281,725,409.60
       其中:营业成本                                       298,881,387.97                         294,604,418.03
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                   4,026,108.72                          13,275,927.41
             销售费用                                           955,468.77                           1,835,553.63
             管理费用                                        37,788,513.77                          23,948,426.05
             财务费用                                        -57,960,946.35                         -51,938,915.52
             资产减值损失
       加   :公允价值变动收益(损失
                                                                                                      -996,444.00以“-”号填列)
             投资收益(损失以“-”号填列)
             其中:对联营企业和合营企业的投资收益
             汇兑收益(损失以“-”号填列)
                                                              深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    三、营业利润(亏损以“-”号填列)                            166,966,664.91                         204,831,023.72
       加   :营业外收入                                          174,340.77                            146,628.60
       减   :营业外支出                                          337,272.54                               7,619.70
             其中:非流动资产处置损
                                                                  336,627.28                               2,244.66失四、利润总额(亏损总额以“-”号填
                                                              166,803,733.14                         204,970,032.62列)
       减:所得税费用                                          28,836,067.23                          33,398,835.27
    五、净利润(净亏损以“-”号填列)                            137,967,665.91                         171,571,197.35
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                             139,102,767.21                         173,549,408.91
       少数股东损益                                             -1,135,101.30                         -1,978,211.56
    六、每股收益:                        --                                        --
       (一)基本每股收益                                               0.17                                   0.22
       (二)稀释每股收益                                               0.17                                   0.22
    七、其他综合收益                                                 -287,903.99                            -315,989.39
    八、综合收益总额                                              137,679,761.92                         171,255,207.96
       归属于母公司所有者的综合收益
                                                              138,814,863.22                         173,233,419.52总额
       归属于少数股东的综合收益总额                             -1,135,101.30                         -1,978,211.56
    法定代表人:李锂                           主管会计工作负责人:孔芸                       会计机构负责人:孔芸4、母公司利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                         单位:元
                  项目                             本期金额                               上期金额
    一、营业收入                                                  444,627,650.37                         487,527,370.59
       减:营业成本                                           288,075,382.42                         294,587,286.61
            营业税金及附加                                      4,026,108.72                          13,275,927.41
            销售费用                                              360,381.18                           1,835,553.63
            管理费用                                           25,970,828.16                          14,865,617.70
            财务费用                                           -56,561,709.82                        -51,754,708.05
            资产减值损失
                                                               深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
       加:公允价值变动收益(损失以
                                                                                                         -996,444.00“-”号填列)
           投资收益(损失以“-”号填
                                                                 1,804,000.00列)
           其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                             184,560,659.71                         213,721,249.29
       加:营业外收入                                               95,741.74                              92,260.61
       减:营业外支出                                                 538.92                                2,244.66
           其中:非流动资产处置损失                                   538.92                                2,244.66三、利润总额(亏损总额以“-”号填
                                                               184,655,862.53                         213,811,265.24列)
       减:所得税费用                                           28,942,007.78                          33,506,809.24
    四、净利润(净亏损以“-”号填列)                             155,713,854.75                         180,304,456.00
    五、每股收益:                          --                                      --
       (一)基本每股收益                                                0.19                                   0.23
       (二)稀释每股收益                                                0.19                                   0.23六、其他综合收益
    七、综合收益总额                                               155,713,854.75                         180,304,456.00
    法定代表人:李锂                             主管会计工作负责人:孔芸                    会计机构负责人:孔芸5、合并现金流量表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                          单位:元
                 项目                               本期金额                               上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                            437,459,547.72                         635,408,044.26
       客户存款和同业存放款项净增加额
       向中央银行借款净增加额
       向其他金融机构拆入资金净增加额
       收到原保险合同保费取得的现金
       收到再保险业务现金净额
       保户储金及投资款净增加额
                                    深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                  40,931,358.13                         12,774,509.05
    收到其他与经营活动有关的现金    47,768,384.72                         66,690,766.39
    经营活动现金流入小计                526,159,290.57                        714,873,319.70
    购买商品、接受劳务支付的现金   415,994,590.14                        148,556,684.60
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     38,968,297.34                         29,674,084.82金
    支付的各项税费                   8,038,692.13                         31,094,576.85
    支付其他与经营活动有关的现金    14,329,086.78                         16,157,214.55
    经营活动现金流出小计                477,330,666.39                        225,482,560.82
    经营活动产生的现金流量净额           48,828,624.18                        489,390,758.88二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金
    处置固定资产、无形资产和其他
                                         10,480.00                              1,380.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                     10,480.00                              1,380.00
    购建固定资产、无形资产和其他
                                    141,469,693.42                         44,360,030.26长期资产支付的现金
    投资支付的现金                  62,160,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
                                                        深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    投资活动现金流出小计                                     203,629,693.42                          44,360,030.26
    投资活动产生的现金流量净额                              -203,619,213.42                          -44,358,650.26三、筹资活动产生的现金流量:
       吸收投资收到的现金                                                                         4,000,000.00
       其中:子公司吸收少数股东投资
                                                                                                  4,000,000.00收到的现金
       取得借款收到的现金                                 76,515,224.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                      76,515,224.00                           4,000,000.00
       偿还债务支付的现金                                149,614,678.16
       分配股利、利润或偿付利息支付
                                                              67,119.55的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                     149,681,797.71
    筹资活动产生的现金流量净额                                -73,166,573.71                          4,000,000.00四、汇率变动对现金及现金等价物的
                                                              -26,889.06                             -33,164.48影响
    五、现金及现金等价物净增加额                            -227,984,052.01                         448,998,944.14
       加:期初现金及现金等价物余额                     6,588,480,677.31                       6,773,837,875.03
    六、期末现金及现金等价物余额                            6,360,496,625.30                       7,222,836,819.17
    法定代表人:李锂                      主管会计工作负责人:孔芸                    会计机构负责人:孔芸6、母公司现金流量表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                     单位:元
                 项目                        本期金额                               上期金额一、经营活动产生的现金流量:
       销售商品、提供劳务收到的现金                      426,647,102.68                         635,536,408.24
       收到的税费返还                                     40,931,358.13                          12,774,509.05
       收到其他与经营活动有关的现金                       46,682,869.40                          76,802,287.24
    经营活动现金流入小计                                     514,261,330.21                         725,113,204.53
                                    深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文
    购买商品、接受劳务支付的现金   415,172,247.97                        145,691,068.63
    支付给职工以及为职工支付的现
                                     30,727,223.38                         25,874,661.84金
    支付的各项税费                    7,694,227.56                        31,051,982.89
    支付其他与经营活动有关的现金    11,031,732.92                         12,529,954.88
    经营活动现金流出小计                464,625,431.83                        215,147,668.24
    经营活动产生的现金流量净额           49,635,898.38                        509,965,536.29二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益所收到的现金          1,804,000.00
    处置固定资产、无形资产和其他
                                             80.00                              1,380.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                   1,804,080.00                             1,380.00
    购建固定资产、无形资产和其他
                                    109,503,739.95                         15,367,152.62长期资产支付的现金
    投资支付的现金                 142,160,000.00                        121,149,500.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                251,663,739.95                        136,516,652.62
    投资活动产生的现金流量净额          -249,859,659.95                      -136,515,272.62三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金              76,515,224.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                 76,515,224.00
    偿还债务支付的现金             149,614,678.16
    分配股利、利润或偿付利息支付
                                         67,119.55的现金
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                149,681,797.71
    筹资活动产生的现金流量净额           -73,166,573.71
                                                      深圳市海普瑞药业股份有限公司 2013 年第一季度报告全文四、汇率变动对现金及现金等价物的
                                                           -23,768.88影响
    五、现金及现金等价物净增加额                          -273,414,104.16                       373,450,263.67
       加:期初现金及现金等价物余额                  6,333,271,651.85                     6,610,843,169.94
    六、期末现金及现金等价物余额                         6,059,857,547.69                     6,984,293,433.61
    法定代表人:李锂                      主管会计工作负责人:孔芸                  会计机构负责人:孔芸二、审计报告
       第一季度报告是否经过审计
       □ 是 √ 否
                                                                        深圳市海普瑞药业股份有限公司
                                                                                                   董事会
                                                                                  二〇一三年四月十八日
数据加载中...
prevnext
手机查看股票